(Q40046843)

PubMed publication ID

18794077

16 September 2017

title

Translational Research Working Group developmental pathway for immune response modifiers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

2

Jeffrey Schlom

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

author name string

Martin A Cheever

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

Louis M Weiner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

Mary L Disis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

Addison Greenwood

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

Oren Grad

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

William G Nelson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

Translational Research Working Group

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

language of work or name

English

0 references

publication date

1 September 2008

1 reference

PubMed publication ID

18794077

16 September 2017

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

page(s)

5692-5699

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine

13 May 2020

cites work

1 reference

12 December 2020

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

12 December 2020

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine

1 reference

12 December 2020

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function

1 reference

12 December 2020

Immunotherapy and chemotherapy--a practical partnership

1 reference

12 December 2020

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

1 reference

12 December 2020

Checkpoint blockade in cancer immunotherapy

1 reference

12 December 2020

Combining Vaccines with Conventional Therapies for Cancer

1 reference

12 December 2020

Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy

1 reference

12 December 2020

Twelve immunotherapy drugs that could cure cancers

1 reference

12 December 2020

Paradigm shifts in cancer vaccine therapy.

1 reference

12 December 2020

1 reference

12 December 2020

The Translational Research Working Group developmental pathways: introduction and overview

1 reference

12 December 2020

Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice.

1 reference

12 December 2020

Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines

1 reference

12 December 2020

Lymphocyte depletion during treatment with intensive chemotherapy for cancer

1 reference

12 December 2020

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

1 reference

12 December 2020

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

1 reference

12 December 2020

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

1 reference

12 December 2020

10.1158/1078-0432.CCR-08-1266

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6383515&resulttype=core&format=json

13 May 2020

PubMed publication ID

18794077

1 reference